Sunday, June 7, 2026

ChatGPT’s New Model Outsmarts 98% of Humans on IQ Test

OpenAI's o3 model scored 136 on the Norwegian Mensa IQ test, but concerns arose over its training data access. A new offline test yielded a score of 116.

Biosimilar Red Tape Showdown: Patient Groups and Insurers Push Congress to End “Interchangeability” Rules After $56B in Savings

U.S. groups urge Congress to eliminate biosimilar interchangeability regulations, boosting access and reducing costs for Korean firms.

US-Iran Ceasefire Boosts Bitcoin: Will Crypto Winter End in 2026?

A ceasefire between the U.S. and Iran boosts major cryptocurrencies, signaling potential recovery from the crypto winter.

Jeong Eun Kim

Author's Latest

Boryung Begins First Global CDMO Supply of Alimta Through Taiwan Partnership

Boryung Pharmaceutical starts supplying Alimta to Lotus, enhancing global CDMO efforts and addressing chemotherapy drug shortages.

ST Pharm Expands Global CDMO Outreach at TIDES USA and ASGCT 2026

ST Pharm showcased its CDMO capabilities at TIDES USA and ASGCT 2026, focusing on nucleic acid therapeutics and strategic partnerships.

MetaVia to Present DA-1726 Phase 1 Obesity Trial Data at EASL Congress 2026

Dong-A ST's Meta via will present DA-1726, a dual-action obesity treatment, at the EASL Congress 2026, showcasing promising clinical trial results.

Samsung Biologics Highlights CRDO and Organoid Platforms at PEGS Boston

Samsung Biologics showcased its CRDO capabilities at PEGS Boston, enhancing cancer drug development with innovative organoid technology.

Novo Nordisk’s Weekly Growth Hormone Sogroya Gains Reimbursement in Korea

Novo Nordisk's Sogroya gains insurance coverage, but market changes may be limited due to strong competitors and safety concerns.

GC MediAI Issues First Profit Guidance Since Founding, Targeting 80% Operating Profit Growth

GC MediAI forecasts 13.5 billion KRW profit in 2026, driven by AI and platform growth, with strong performance in medical sectors.

Samsung Biologics Named Dow Jones Best-in-Class World Index for Fifth Straight Year

Samsung Biologics has been recognized in the Dow Jones Best-in-Class World Index for five consecutive years, showcasing its ESG achievements.

Artiva to Advance NK Cell Therapy Into Phase 3 for Rheumatoid Arthritis After Positive Mid-Stage Data

GC Cell's Artiva Biotherapeutics advances NK cell therapy AlloNK to Phase 3 trials for rheumatoid arthritis after promising Phase 2 results.

Novo Nordisk’s Oral Wegovy Just Put Up a Number That Could Change the Obesity Drug Race

Novo Nordisk's oral obesity treatment, Wegovy, saw $400M in Q1 2026 sales, exceeding estimates and indicating strong market demand.

A Long-Acting Oral Drug? Yuhan’s Latest Trial Update Is Turning Heads

Yuhan Corp's YH35995 shows promising results for Gaucher disease in Phase 1 trial, demonstrating long-lasting efficacy and BBB penetration.

A Record Year in China Is Giving Hanmi Pharmaceutical More Firepower for What’s Next

Hanmi Pharmaceutical's Chinese subsidiary surpassed $290M in sales, contributing significantly to the group's growth and future investments.

CG Bio Group Launches Acellular Dermal Matrix-based Product Reallo Inject Fine

CG Bio launches Reallo Inject Fine, an acellular dermal matrix product, enhancing usability for medical professionals and expanding applications.

Korean MSD Partners with 13 Biotech Firms to Act as Global Collaboration Hub

Korean MSD held an Open Innovation Week to enhance collaboration with local biotech firms, aiming for technology exchanges and joint research.

GC Cell Secures Japanese Certification for the Manufacture of Specific Cell Processing Products

GC Cell receives final certification from Japan for cell processing products, validating its manufacturing and quality systems for regenerative medicine.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.